The outlook of companies tied to the drug's past presents a challenging investment picture . While the initial surge generated substantial returns , generic copies have significantly diminished market share . Investing in connected pharmaceutical companies now requires a thorough assessment of patent safeguards, evolving healthcare trends , and the